Davis Capital Management
INDV icon

Davis Capital Management’s Indivior Pharmaceuticals INDV Stock Holding History

Davis Capital Management’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$36 Sell
1
-6
-86% -$227 ﹤0.01% 1159
2026
Q2 		$287 Buy
+7
New +$254 ﹤0.01% 742

Other funds holding INDV

Two Seas Capital
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
BI Asset Management Fondsmaeglerselskab
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $13.1B AUM 35.37% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return
Exchange Traded Concepts
Exchange Traded Concepts Oklahoma City, Oklahoma $25.3B AUM 51.52% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

Davis Capital Management's INDV Position: Q3 2026 in Review

Davis Capital Management reduced its Indivior Pharmaceuticals (INDV) stake by 86% in Q3 2026, selling an estimated $227 and leaving 1 share worth $36. The position accounts for ﹤0.01% of the portfolio, ranked #1159.

Davis Capital Management first reported a position in INDV in Q2 2026 and has held it in 2 quarters since. The position peaked at $287 in Q2 2026. 66 funds tracked by Wall St. Rank hold INDV as of Q3 2026.

  • Davis Capital Management held 1 share of Indivior Pharmaceuticals worth $36 as of Q3 2026.
  • Davis Capital Management sold 6 Indivior Pharmaceuticals shares in Q3 2026, an estimated $227.
  • Indivior Pharmaceuticals made up ﹤0.01% of Davis Capital Management's portfolio in Q3 2026, its #1159 holding.
  • Davis Capital Management first reported a position in Indivior Pharmaceuticals in Q2 2026 and has held it in 2 quarters since.
  • Davis Capital Management's Indivior Pharmaceuticals position peaked at $287 in Q2 2026.
  • 66 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q3 2026.

Based on Davis Capital Management's 13F filing for Q3 2026, filed 8 Oct 2026.